Leaflet METLINKA 50mg / 850mg film-coated tablets
- Product code:
- W70789001
- Quantity:
- 14
- Indicated for:
- type 2 diabetes mellitus
- Route of administration:
- oral
- Substance:
- sitagliptin (DPP-4 inhibitor)
- ATC
- A10BD07 — Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Combinations of oral blood glucose lowering drugs
Sitagliptin is a medication used to treat type 2 diabetes. It belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the levels of incretin hormones. These hormones stimulate insulin secretion and reduce glucagon production, thereby lowering blood sugar levels, especially after meals.
Sitagliptin is taken orally, usually once daily, with or without food. It is used either as monotherapy or in combination with other antidiabetic medications, such as metformin or sulfonylureas, to improve glycemic control.
Common side effects include headaches, upper respiratory tract infections, nasal congestion, and abdominal pain. In rare cases, it may cause more serious reactions, such as pancreatitis, severe allergic reactions (angioedema, urticaria), or severe joint pain.
Sitagliptin is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis. It is important for patients to follow their doctor's recommendations, regularly monitor blood sugar levels, and report any adverse reactions or changes in health.
Sitagliptin is taken orally, usually once daily, with or without food. It is used either as monotherapy or in combination with other antidiabetic medications, such as metformin or sulfonylureas, to improve glycemic control.
Common side effects include headaches, upper respiratory tract infections, nasal congestion, and abdominal pain. In rare cases, it may cause more serious reactions, such as pancreatitis, severe allergic reactions (angioedema, urticaria), or severe joint pain.
Sitagliptin is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis. It is important for patients to follow their doctor's recommendations, regularly monitor blood sugar levels, and report any adverse reactions or changes in health.
General data about METLINKA 50mg / 850mg
- Substance:
- sitagliptin
- Date of latest medicines list:
- 01-01-2025
- Product code:
- W70789001
- Concentration:
- 50mg / 850mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 14
- Product type:
- Generic medicine
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for sitagliptin
Concentrations available for sitagliptin
- 100mg
- 25mg
- 25mg/ml
- 50mg
- 50mg/1000mg
- 50mg/850mg